Growth Stocks
Growth stocks are money machines that generate substantial—and sustainable—positive cash flow, and whose revenues and earnings are expected to increase at faster rates than the average company.
Growth companies typically have some sort of competitive advantage that allows them to fend off competitors and keep the lion’s share of business to themselves. They also have many different investment opportunities (or a few large opportunities) that promise to generate high returns.
Uncover a variety of top picks in growth stocks and the hottest growth trends, past and present, in our growth investing article archive below. Also, be sure to check out our exclusive free guide on the top growth stocks to own now, featuring three top growth stocks that we believe will be worth much more in the future than they cost today.
For Gold Bears, It’s Deja Vu All Over Again
Gold bears have begun to party as if it’s 1999.
Coping with the Cyprus Effect
The banking crisis in Cyprus has ramifications for investors everywhere. Here are the best ways to find safety in today’s risky financial environment.
Recycling Profits
This maker of clothing from recycled materials will rake in the profits as the economy rebounds.
A Breakthrough for Obesity?
This innovative drug could finally help Americans prevail against their ever-expanding waistlines.
Why Some Energy Companies Flounder
As many investors have found out this year, not all energy companies are equal.
Cyprus, the Universe and the Telephone Game
If the story from Cyprus is anything, it's a warning.
Look for Landec to Leap
This stock is still a great value, following lower guidance.
Profiting from Rules and Regulations
Although government regulation sometimes stifles innovation, healthcare investors can still exploit its tendency to create winners and losers.
Cyprus, the Euro and You
Here’s what the latest euro zone crisis really means for investors.
Healthcare Goes to the Dogs
Animal healthcare is becoming an increasingly lucrative business, and many of the major drugmakers already operate in this arena. In fact, Pfizer recently spun off its animal healthcare division, which is now a standalone company with a $16 billion market cap.
